Skip to main content
Clinical Trials/NCT02443350
NCT02443350
Unknown
Not Applicable

Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area

Jia Wei Wang,MD1 site in 1 country400 target enrollmentJune 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Sponsor
Jia Wei Wang,MD
Enrollment
400
Locations
1
Primary Endpoint
death
Last Updated
10 years ago

Overview

Brief Summary

Anti N-methyl-D-aspartate receptor encephalitis is an autoimmune encephalitis,found in recent years,producing the specific IgG antibody induced by the NMDA receptors.It is the most common curable disease among the non infectious-autoimmune encephalitis,usually has been misdiagnosed as other causes of encephalitis.Our previous study found that there are differences between the Chinese and the foreign in anti-NMDA receptor encephalitis such as the sex ratio, the rate of combined tumor and clinical manifestations.As a new found disease,the incidence rate has been underestimated.Therefore,to establish the Registry Research Database for Chinese group of anti-NMDA receptor encephalitis is imminent.This study will combine Beijing area's hospitals and foreign experts,depending on multicenter, prospective and registry method,to understand the incidence in Beijing area,to summarize and analyze the clinical data of patients.So,there will make a solid foundation for the subsequent Beijing area detection platform and other research.

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
May 2017
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Jia Wei Wang,MD
Responsible Party
Sponsor Investigator
Principal Investigator

Jia Wei Wang,MD

M.D.;The head of Department of Neurology and Medical Research Center

Beijing Tongren Hospital

Eligibility Criteria

Inclusion Criteria

  • Older than 6 months.
  • Encephalopathy symptoms (change of mental state and consciousness level) persist for more than 24 hours;
  • At least one or more clinical features of the followings: fever, epilepsy, focal neurological deficiency symptoms, changes in CSF(cerebrospinal fluid inflammatory), changes in EEG (electroencephalogram), radiographic abnormalities;
  • Clinical suspected encephalitis, but conventional detected methods cannot make etiology clear

Exclusion Criteria

  • Infants less than 6 months;
  • The metabolic encephalopathy;
  • Infectious encephalitis with clinically clear pathogen, referring the specific pathogenic microorganisms, including: bacteria, virus, fungus, parasite, spirochete and so on;
  • Non-infectious encephalitis with clinically clear diagnosis, including: multiple sclerosis, optic neuromyelitis, acute disseminated encephalomyelitis and so on.

Outcomes

Primary Outcomes

death

Time Frame: 24 months

Study Sites (1)

Loading locations...

Similar Trials